ArticleEuropean journal of pediatrics2006
Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine.
Article in European journal of pediatrics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.Drugs in R&D · 2017Pooled it
- The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.Science advances · 2023Trial
- Imidazopyridine derivatives as promising anti-RSC advances · 2026Article
- Addressing printability of poorly flowable drug by wet granulation: understanding interplays of formulation and process variables on critical quality attributes of sulfadiazine printlets.International journal of pharmaceutics · 2026Article
- Nephrolithiasis associated with sulfadiazine therapy in an infant with congenital toxoplasmosis: a case report.BMC pediatrics · 2026Article
- Protective Effect of S-Methylcysteine Against Toxoplasma gondii-Induced Reproductive Toxicity in Female Albino Rats.Acta parasitologica · 2025Article
- Prophylactic Effect of Microwave Radiation onJournal of parasitology research · 2025Article
- Glabridin exhibits potent inhibitory effects against Toxoplasma gondii in vitro and in vivo.Parasites & vectors · 2024Article
- REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015-2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns.PLoS neglected tropical diseases · 2024Observational
- Functional Characterization of 11 Tentative Microneme Proteins in Type I RH Strain ofAnimals : an open access journal from MDPI · 2024Article
- In Vitro Evaluation of Anti-Parasitic Activities of Quinolone-Coumarin Hybrids Derived from Fluoroquinolones and Novobiocin Against Toxoplasma gondii.Acta parasitologica · 2024Article
- Effective factors in the pathogenesis ofHeliyon · 2024Review
- The Brazilian Toxoplasma gondii strain BRI caused greater inflammation and impairment in anxiogenic behavior in mice, which was reverted by rosuvastatin treatment.Parasitology research · 2023Article
- In Vitro and In Vivo Anti-parasitic Activity of Sambucus ebulus and Feijoa sellowiana Extracts Silver Nanoparticles on Toxoplasma gondii Tachyzoites.Acta parasitologica · 2023Article
- Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity.Expert opinion on drug delivery · 2023Article
- Anti-Toxoplasma Activities of Some Egyptian Plant Extracts: An In Vitro Study.Acta parasitologica · 2022Article
- Congenital toxoplasmosis: Should we still care about screening?Food and waterborne parasitology · 2022Article
- Toxoplasmosis: Current and Emerging Parasite Druggable Targets.Microorganisms · 2021Review
- Comprehensive Overview ofPathogens (Basel, Switzerland) · 2021Review
- Effect of some plant extracts from Egyptian herbal plants against Toxoplasma gondii tachyzoites in vitro.The Journal of veterinary medical science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim was to study the tolerability and plasma concentrations of pyrimethamine and sulfadiazine in children treated for congenital toxoplasmosis. Infants were diagnosed through the Danish Toxoplasma Neonatal Screening Programme, based on detection of toxoplasma-specific IgM- and/or IgA-antibodies on 3 mm blood spots collected from phenylketonuria [PKU cards (Guthrie cards)]. Toxoplasma-infected children received 3 months' continuous treatment with 50-100 mg/kg per day sulfadiazine in two separate administrations and 1 mg/kg per day pyrimethamine after a 1-day loading dose of 2 mg/kg, and folinic acid 7.5 mg was administered twice weekly. Blood cell counts and body weight were recorded during follow-up. The plasma concentrations of pyrimethamine and sulfadiazine were analysed in a subgroup of seven children, using high performance liquid chromatography with ultraviolet and mass spectrometric detection. Of 48 infants, 41 completed the treatment without change in schedule. Six infants had neutrophil counts below 0.5x10(9)/l, and one infant had an elevated bilirubin value. Twenty-nine children were tested by a series of neutrophil counts during treatment. The neutrophil count was <or=0.5x10(9)/l or lower in 4/29 (13.8%). None of the children had anaemia or thrombocytopenia. The drugs did not affect weight gain. Mean plasma drug concentrations varied between 1.3 microg/ml and 2.2 microg/ml for pyrimethamine and between 60 microg/ml and 86 microg/ml for sulfadiazine. Treatment efficacy is still a concern, since progression of eye lesions was observed in three eyes during the follow-up period. We concluded that the treatment was well tolerated in 86% (25/29) of the children. The drugs did not affect their weight gain. Drugs given in the recommended doses led to concentrations within expected therapeutic limits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.